The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Buprenorphine Treatment of Refractory Depression
Abstract
Opiates were used to treat major depression until the mid-1950s. The advent of opioids with mixed agonist-antagonist or partial agonist activity, with reduced dependence and abuse liabilities, has made possible the reevaluation of opioids for this indication. This is of potential importance for the population of depressed patients who are unresponsive to or intolerant of conventional antidepressant agents. Ten subjects with treatment-refractory, unipolar, nonpsychotic, major depression were treated with the opioid partial agonist buprenorphine in an open-label study. Three subjects were unable to tolerate more than two doses because of side effects including malaise, nausea, and dysphoria. The remaining seven completed 4 to 6 weeks of treatment and as a group showed clinically striking improvement in both subjective and objective measures of depression. Much of this improvement was observed by the end of 1 week of treatment and persisted throughout the trial. Four subjects achieved complete remission of symptoms by the end of the trial (Hamilton Rating Scale for Depression scores < or = 6), two were moderately improved, and one deteriorated. These findings suggest a possible role for buprenorphine in treating refractory depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Buprenorphine has antidepressant effects when used for both opioid use disorder and treatment-resistant depression (279-284)”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [279]
In the citing paper
“Overall, six clinical trials [41,42,43,44,45,46]—of which three were randomized, double-blind and placebo controlled studies [41,44,45]—and one clinical case [47], including a total of 216 subjects with TRD treated with BUP in mono-therapy or together with an opioid antagonist (naloxone or samidorphan) were included.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“Bodkin [42] treated 10 TRD subjects with BUP, according to tolerance and clinical benefits, with a maximum daily dosage of 1.8 mg. After four to six weeks, seven patients showed clinically striking improvements in both subjective and objective measures of depression.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“Taken together, according to the included studies, BUP has a rapid antidepressant and anti-suicidal action: in fact, this psychoactive compound seems to act in about a week after the first administration [41,42,43,44,46,47,48,52].”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“Bodkin and colleagues [42] and Gerra et al. [50] even reported some cases of irritability, anxiety, and dysphoria, which led to drop-out from the study of implicated patients.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“Not all the studies included in this review analyzed the occurrence of side effects related to BUP use but, in those who considered their possible emergence [42,43,44,45,46,50,51], specific side-effects were described in the majority of patients.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
In the citing paper
“On the other hand, there are also studies [42,47,48,50,51] suggesting that this action is prolonged in time up to one to three months.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [42]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Opioid analgesics and antagonists
Reisine, T. (1996) · Medical Entomology and Zoology · Cited by 1,205
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA · doi:10.1001/jama.1992.03480200058024 · Cited by 567
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Buprenorphine suppresses heroin use by heroin addicts
Mello, N. K., & Mendelson, J. H. (1980) · Science · doi:10.1126/science.7352279 · Cited by 298
Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel, W. K., Stitzer, M. L., Bigelow, G. E., Liebson, I. A., Jasinski, D. R., & Johnson, R. E. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20047-7 · Cited by 226
Regionally selective increases in μ opioid receptor density in the brains of suicide victims
Gross‐Isseroff, R., Dillon, K. A., Israeli, M., & Biegon, A. R. (1990) · Brain Research · doi:10.1016/0006-8993(90)91301-v · Cited by 221
(1990) · PubMed · Cited by 199
A controlled trial of buprenorphine treatment for opioid dependence
Johnson, R. E. (1992) · JAMA · doi:10.1001/jama.267.20.2750 · Cited by 199
Research works printed but not linked: 8
- Carlson, 1963, Am J Psychiatry, 112-, 7
- Lehmann, 1971, Curr Ther Res, 13, 42
- Exstein, 1981, Psychopharmacol Bull, 17, 29
- Resnick, 1992, Psychopharmacol Bull, 28, 109
- Banks, 1979, N Z Med J, 89, 255
- Thase, 1992, J Clin Psychiatry, 53, 5
- Bickel, 1988, J Psychopharmacol Exp Ther, 247, 47
- Harrison, 1988, Psychopharmacol Bull, 24, 9
Cited by
Sorted by citations
Affective consciousness: core emotional feelings in animals and humans.
Panksepp, J. (2005) · Consciousness and Cognition · doi:10.1016/j.concog.2004.10.004 · Cited by 1,217
depue, R. A., & morrone-strupinsky, J. V. (2005) · Behavioral and Brain Sciences · doi:10.1017/s0140525x05000063 · Cited by 958
The basic emotional circuits of mammalian brains: Do animals have affective lives?
Panksepp, J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.08.003 · Cited by 588
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 569
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
NK1 (substance P) receptor antagonists – why are they not analgesic in humans?
Hill, R. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01502-9 · Cited by 462
Association Between Mental Health Disorders, Problem Drug Use, and Regular Prescription Opioid Use
Sullivan, M. D., Edlund, M. J., Zhang, L., Unützer, J., & Wells, K. B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2087 · Cited by 436
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Ruhm, C. J. (2015) · Journal of Health Economics · doi:10.1016/j.jhealeco.2015.03.004 · Cited by 361
Kruegel, A. C., Gassaway, M. M., Kapoor, A., Váradi, A., Majumdar, S., Filizola, M., Javitch, J. A., & Sameš, D. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b00360 · Cited by 327
Macroeconomic conditions and opioid abuse
Hollingsworth, A. J., Ruhm, C. J., & Simon, K. I. (2017) · Journal of Health Economics · doi:10.1016/j.jhealeco.2017.07.009 · Cited by 307
Yovell, Y., Bar, G., Mashiah, M., Baruch, Y., Briskman, I., Asherov, J., Lotan, A., Rigbi, A., & Panksepp, J. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040535 · Cited by 311
Panksepp, J. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.4/jpanksepp · Cited by 327
Buprenorphine: Considerations for Pain Management
Johnson, R. E., Fudala, P. J., & Payne, R. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.07.005 · Cited by 290
Stress models of depression: forming genetically vulnerable strains
Henn, F. A., & Vollmayr, B. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.019 · Cited by 274
Role of kappa-opioid receptors in stress and anxiety-related behavior
Veer, A. V., & Carlezon, W. A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3195-5 · Cited by 262
The Endomorphin System and Its Evolving Neurophysiological Role
Fichna, J., Janecka, A. E., Costentin, J., & do-Rego, J.-C. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.1.3 · Cited by 249
Regular use of prescribed opioids: Association with common psychiatric disorders
Sullivan, M. D., Edlund, M. J., Steffick, D., & Unützer, J. (2005) · Pain · doi:10.1016/j.pain.2005.09.020 · Cited by 231
Grattan, A., Sullivan, M. D., Saunders, K. W., Campbell, C. I., & Von Korff, M. R. (2012) · The Annals of Family Medicine · doi:10.1370/afm.1371 · Cited by 226
Long-term retention in Office Based Opioid Treatment with buprenorphine
Weinstein, Z., Kim, H. W., Cheng, D. M., Quinn, E. K., Hui, D. S. C., LaBelle, C. T., Drainoni, M., Bachman, S. S., & Samet, J. H. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2016.12.010 · Cited by 224
Northoff, G., Wiebking, C., Feinberg, T., & Panksepp, J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.12.007 · Cited by 222
A brain-centric model of suicidal behavior
Mann, J. J., & Rizk, M. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081224 · Cited by 214
Lutfy, K., Eitan, S., Bryant, C. D., Yang, Y. C., Saliminejad, N., Walwyn, W., Kieffer, B. L., Takeshima, H., Carroll, F. I., Maidment, N. T., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-32-10331.2003 · Cited by 211
Watt, D. F., & Panksepp, J. (2009) · Neuropsychoanalysis · doi:10.1080/15294145.2009.10773593 · Cited by 216
Panksepp, J., & Watt, D. (2011) · Psychiatry: Interpersonal and Biological Processes · doi:10.1521/psyc.2011.74.1.5 · Cited by 207
Witkin, J. M., Statnick, M. A., Rorick‐Kehn, L. M., Pintar, J. E., Ansonoff, M. A., Chen, Y., Tucker, R. C., & Ciccocioppo, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.011 · Cited by 197
Karp, J. F., Butters, M. A., Begley, A. E., Miller, M. D., Lenze, E. J., Blumberger, D. M., Mulsant, B. H., & Reynolds, C. F. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08725 · Cited by 191
Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches
Peciña, M., Karp, J. F., Mathew, S. J., Todtenkopf, M. S., Ehrich, E. W., & Zubieta, J.-K. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0117-2 · Cited by 197
Invited review: the evolution of antidepressant mechanisms
Slattery, D. A., Hudson, A. L., & Nutt, D. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00195.x · Cited by 185
Panksepp, J. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.02.015 · Cited by 188
Opioid system and human emotions
Nummenmaa, L., & Tuominen, L. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13812 · Cited by 178
Evaluation of Opioid Modulation in Major Depressive Disorder
Ehrich, E., Turncliff, R., Du, Y., Leigh-Pemberton, R., Fernandez, E., Jones, R., & Fava, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.330 · Cited by 169
Wright, J. S., & Panksepp, J. (2012) · Neuropsychoanalysis · doi:10.1080/15294145.2012.10773683 · Cited by 172
Gewirtz, J. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00136-6 · Cited by 164
Suicide Risk and Addiction: The Impact of Alcohol and Opioid Use Disorders
Rizk, M., Herzog, S., Dugad, S., & Stanley, B. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00361-z · Cited by 195
Serafini, G., Adavastro, G., Canepa, G., De Berardis, D., Valchera, A., Pompili, M., Nasrallah, H., & Amore, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082410 · Cited by 162
Development of κ Opioid Receptor Antagonists
Carroll, F. I., & Carlezon, W. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301783x · Cited by 166
Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials
Carlezon, W. A., & Krystal, A. D. (2016) · Depression and Anxiety · doi:10.1002/da.22500 · Cited by 165
Treatment of depression in patients with opiate dependence
Nunes, E. V., Sullivan, M. A., & LEVIN, F. R. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.037 · Cited by 158
Kappa-opioid ligands in the study and treatment of mood disorders
Carlezon, W. A., Béguin, C., Knoll, A. T., & Cohen, B. M. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.008 · Cited by 156
D, M. F. M., & Rush, A. J. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000091771 · Cited by 151
Buprenorphine: a controlled clinical trial in the treatment of opioid dependence
Pani, P., Maremmani, I., Pirastu, R., Tagliamonte, A., & Gessa, G. L. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00140-4 · Cited by 149
Neurobiology of opioid dependence in creating addiction vulnerability
Evans, C. J., & Cahill, C. M. (2016) · F1000Research · doi:10.12688/f1000research.8369.1 · Cited by 146
Psychotherapeutic Benefits of Opioid Agonist Therapy
Tenore, P. L. (2008) · Journal of Addictive Diseases · doi:10.1080/10550880802122646 · Cited by 143
Selected Principles of Pankseppian Affective Neuroscience
Davis, K. L., & Montag, C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01025 · Cited by 159
Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome
Gerra, G., Borella, F., Zaimovic, A., Moi, G., Bussandri, M., Bubici, C., & Bertacca, S. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.11.017 · Cited by 141
Buprenorphine Use: The International Experience
Carrieri, P., Amass, L., Lucas, G. M., Vlahov, D., Wodak, A., & WOODY, G. E. (2006) · Clinical Infectious Diseases · doi:10.1086/508184 · Cited by 142
Augmentation and combination strategies in treatment-resistant depression.
D, M. F. M. (2001) · PubMed · Cited by 141
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
Davis, M. P., Pasternak, G., & Behm, B. (2018) · Drugs · doi:10.1007/s40265-018-0953-z · Cited by 138
Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction
Chartoff, E. H., & Mavrikaki, M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00466 · Cited by 137
Berrocoso, E., Sánchez‐Blázquez, P., Garzón, J., & Micó, J. A. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168100 · Cited by 131
Pharmacological properties of JDTic: a novel κ-opioid receptor antagonist
Carroll, I. F., Thomas, J. B., Dykstra, L., Granger, A. L., Allen, R. M., Howard, J. L., Pollard, G. T., Aceto, M. D. G., & Harris, L. S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.08.028 · Cited by 125
Emotional causes and consequences of social-affective vocalization
(2010) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-374593-4.00020-6 · Cited by 123
Dreifuss, J. A., Griffin, M. L., Frost, K. H., Fitzmaurice, G. M., Potter, J. S., Fiellin, D. A., Selzer, J. A., Hatch‐Maillette, M. A., Sonne, S. C., & Weiss, R. D. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.010 · Cited by 122
Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors
Falcon, E., Browne, C. A., Leon, R. M., Fleites, V. C., Sweeney, R., Kirby, L. G., & Lucki, I. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.38 · Cited by 118
Howe, C. Q., & Sullivan, M. D. (2013) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2013.10.003 · Cited by 114
Zellner, M. R., Watt, D. F., Solms, M., & Panksepp, J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.01.003 · Cited by 112
Carvalho, A. F., Cavalcante, J. L., Castelo, M. S., & Lima, M. C. O. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00846.x · Cited by 110
Hollander, M. A. G., Chang, C. H., Douaihy, A. B., Hulsey, E. G., & Donohue, J. M. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108927 · Cited by 107
Rojas-Corrales, M. O., Berrocoso, E., Gibert‐Rahola, J., & Micó, J. A. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02220-8 · Cited by 107
Naltrexone and buprenorphine combination in the treatment of opioid dependence
Gerra, G., Fantoma, A., & Zaimovic, A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060835 · Cited by 106
Zomkowski, A. D. E., Santos, A. R. S., & Rodrigues, A. L. S. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.02.026 · Cited by 105
Treatment Augmentation With Opiates in Severe and Refractory Major Depression
Stoll, A. L., & Rueter, S. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.2017 · Cited by 102
A Word to the Wise About Ketamine
Schatzberg, A. F. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101434 · Cited by 102
Faster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 104
Biomarkers of Epileptogenesis: Psychiatric Comorbidities (?)
Kanner, A. M., Mazarati, A. M., & Koepp, M. J. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0271-4 · Cited by 104
The opioid system in depression
Jelen, L. A., Stone, J. M., Young, A. H., & Mehta, M. A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104800 · Cited by 108
Tejedor‐Real, P., Micó, J. A., Smadja, C., Maldonado, R. J., Roques, B. P., & Gibert‐Rahola, J. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00423-3 · Cited by 99
Targeting opioid dysregulation in depression for the development of novel therapeutics
Browne, C. A., & Lucki, I. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.009 · Cited by 100
Assessment and treatment of mood disorders in the context of substance abuse
Tolliver, B. K., & Anton, R. F. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/btolliver · Cited by 105
Active behaviours produced by antidepressants and opioids in the mouse tail suspension test
Berrocoso, E., Ikeda, K., Sora, I., Uhl, G. R., Sánchez‐Blázquez, P., & Micó, J. A. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001842 · Cited by 95
Maxwell, M. A., & Cole, D. A. (2009) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.01.007 · Cited by 99
Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers
Schuman‐Olivier, Z., Albanese, M. A., Nelson, S. E., Roland, L., Puopolo, F., Klinker, L., & Shaffer, H. J. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.03.014 · Cited by 94
Marek, G. J., & Aghajanian, G. K. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00036-5 · Cited by 96
Buprenorphine in the treatment of opioid dependence
Davids, E. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)00146-9 · Cited by 91
Tramadol induces antidepressant-type effects in mice
Rojas-Corrales, M. O., Gibert‐Rahola, J., & Micó, J. A. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00369-5 · Cited by 93
Effects of opioid- and non-opioid analgesics on responses to psychosocial stress in humans
Bershad, A. K., Miller, M. A., Norman, G. J., & de Wit, H. (2018) · Hormones and Behavior · doi:10.1016/j.yhbeh.2018.04.009 · Cited by 92
Lowe, S. L., Wong, C. J., Witcher, J., Gonzales, C., Dickinson, G. L., Bell, R. L., Rorick‐Kehn, L. M., Weller, M., Stoltz, R. R., Royalty, J. E., et al. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.286 · Cited by 90
Opiate Treatment in Depression Refractory to Antidepressants and Electroconvulsive Therapy
Nyhuis, P. W., Gastpar, M., & Scherbaum, N. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818638a4 · Cited by 90
The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
Aquino, J. P. D., Parida, S., & Sofuoglu, M. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01032-7 · Cited by 89
Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study
Gerra, G., Leonardi, C., D'Amore, A., Strepparola, G., Fagetti, R., Assi, C., Zaimovic, A., & Lucchini, A. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.10.007 · Cited by 88
Marek, G. J., & Aghajanian, G. K. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00043-8 · Cited by 89
Prognostic Factors in Buprenorphine- versus Methadone-Maintained Patients
Schottenfeld, R. S., Pakes, J., & Kosten, T. R. (1998) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199801000-00006 · Cited by 87
Predictors of early dropout in outpatient buprenorphine/naloxone treatment
Marcovitz, D. E., McHugh, R. K., Volpe, J., Votaw, V. R., & Connery, H. S. (2016) · American Journal on Addictions · doi:10.1111/ajad.12414 · Cited by 92
Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety
Nummenmaa, L., Karjalainen, T., Isojärvi, J., Kantonen, T., Tuisku, J., Kaasinen, V., Joutsa, J., Nuutila, P., Kalliokoski, K. K., Hirvonen, J., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0725-9 · Cited by 85
Schmid, C. L., Streicher, J. M., Groer, C. E., Munro, T. A., Zhou, L., & Bohn, L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.476234 · Cited by 86
Naltrexone and Dysphoria: Fact or Myth?
Miotto, K. A., McCann, M., Basch, J., Rawson, R. A., & Ling, W. W. (2002) · American Journal on Addictions · doi:10.1080/10550490290087929 · Cited by 86
Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice
Falcón, E., Maier, K. L., Robinson, S. A., Hill‐Smith, T. E., & Lucki, I. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3723-y · Cited by 87
D, M. F. M., Thase, M. E., Trivedi, M. H., Ehrich, E. W., Martin, W. F., Memisoglu, A., Nangia, N., Stanford, A. D., Yu, M., & Pathak, S. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0284-1 · Cited by 83
Dean, A. J., Bell, J., Christie, M. J., & Mattick, R. P. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.09.002 · Cited by 78
Efficacy of pain treatment on mood syndrome in patients with dementia: a randomized clinical trial
Husebo, B. S., Ballard, C. G., Fritze, F., Sandvik, R. K. N. M., & Aarsland, D. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4063 · Cited by 85
Association between gene variants and response to buprenorphine maintenance treatment
Gerra, G., Somaini, L., Leonardi, C., Cortese, E., Maremmani, I., Manfredini, M., & Donnini, C. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.11.001 · Cited by 79
The influence of ketamine on drug discovery in depression
Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate, C. A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.007 · Cited by 75
Witkin, J. M., Martin, A. E., Golani, L. K., Xu, N. Z., & Smith, J. L. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.03.002 · Cited by 80
Investigational drugs in recent clinical trials for treatment-resistant depression
Garay, R. P., Zarate, C. A., Charpeaud, T., Citrome, L., Correll, C. U., Hameg, A., & Llorca, P. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1283217 · Cited by 76
Determining Effective Methadone Doses for Individual Opioid-Dependent Patients
Trafton, J. A., Minkel, J. D., & Humphreys, K. N. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030080 · Cited by 73
Caraci, F., Calabrese, F., Molteni, R., Bartova, L., Dold, M., Leggio, G. M., Fabbri, C., Mendlewicz, J., Racagni, G., Kasper, S. F., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014977 · Cited by 76
Novel Pharmacological Approaches to the Treatment of Depression
Elias, E., Zhang, A. Y., & Manners, M. T. (2022) · Life · doi:10.3390/life12020196 · Cited by 77
Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Rosenblat, J. D., McIntyre, R. S., Alves, G. S., Fountoulakis, K. Ν., & Carvalho, A. F. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630175044 · Cited by 72
Kappa Opioid Receptor Antagonists as Potential Therapeutics for Stress-Related Disorders
Jacobson, M. L., Browne, C. A., & Lucki, I. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023317 · Cited by 70
Metadata
- Authors
- Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O.
- Affiliations
- Harvard University (US)
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1995-02
- Volume
- 15
- Issue
- 1
- Pages
- 49-57
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2063621859
- Cited by
- 346
- References
- 39
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 9 · 2020: 19 · 2019: 22 · 2018: 25 · 2017: 18 · 2016: 20 · 2015: 20 · 2014: 21 · 2013: 18 · 2012: 13
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (DA-00115)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- buprenorphine, treatment-resistant depression, major depressive disorder, antidepressant treatment, opioid side effects
- MeSH terms
- Adult, Aged, Buprenorphine, Depressive Disorder, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
